N-arachidonoylethanolamine (AEA) · (5Z,8Z,11Z,14Z)-N-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide · MW 347.54 g/mol · C₂₂H₃₇NO₂ · CAS 94421-68-8 · ChEMBL15848
Anandamide — the "bliss molecule." From Sanskrit ānanda, "joy/bliss" · the first endogenous cannabinoid ever isolated (Devane & Mechoulam, 1992) · an arachidonic-acid-derived signaling lipid that is the body's own THC — a CB1 partial agonist made on demand, acting for seconds, then hydrolyzed. Not a street drug: it is the natural ligand the plant cannabinoids imitate.
Anandamide is the endogenous molecule the cannabis plant hijacks. It is a partial agonist at the CB1 receptor — the same Gi/o-coupled GPCR that Δ⁹-THC engages — but where THC arrives from outside and lingers, anandamide is manufactured on demand, in the membrane, exactly where and when it is needed, then destroyed within seconds. It is not stored in vesicles: it is the signal and the timer at once.
Postsynaptic depolarization and Ca²⁺ influx drive cleavage of the membrane phospholipid NAPE by NAPE-PLD, liberating anandamide directly into the bilayer. There is no vesicular pool — production is the trigger.
Being lipophilic, AEA diffuses backward across the synapse from the postsynaptic to the presynaptic membrane — the defining feature of endocannabinoid signaling (DSI/DSE: depolarization-induced suppression of inhibition/excitation).
At presynaptic CB1, AEA inhibits adenylyl cyclase (cAMP ↓), and liberated Gβγ closes N/P/Q-type Ca²⁺ channels and opens GIRK K⁺ channels — vesicle fusion falls, transmitter release is suppressed.
AEA binds CB1 well (~72 nM) but activates submaximally — a low-efficacy partial agonist, weaker than 2-AG (the higher-efficacy, far more abundant endocannabinoid) and than synthetic full agonists. Tone, not saturation.
AEA is a weaker partial agonist at immune CB2 (~180 nM) and — uniquely among cannabinoids — an intracellular agonist at the TRPV1 capsaicin channel, making it a true "endovanilloid" bridging two signaling systems.
The signal is switched off by fatty-acid amide hydrolase (FAAH), which hydrolyzes AEA to arachidonic acid + ethanolamine. This rapid, local clearance is why anandamide is fleeting — and why blocking FAAH is a drug strategy.
The contrast with THC is the whole story. THC's affinity is similar, but its exogenous, sustained occupancy produces tonic, diffuse, whole-brain CB1 activation — intoxication. Anandamide's endogenous, pulsatile, synapse-specific release produces modulation: it fine-tunes release probability at the exact terminals that just fired. Same receptor, opposite temporal logic.
Anandamide has no classical pharmacokinetics — there is no dose, no absorption, no plasma half-life in the drug sense. Its "PK" is a local metabolic loop: synthesized in the membrane where it acts, cleared by an enzyme sitting on the postsynaptic membrane. The numbers below describe the endogenous molecule; the small resting plasma pool is a spillover of this local signaling, not a delivery route.
Degradation cascade: the dominant route is FAAH hydrolysis of the amide bond; the arachidonic acid released can re-enter eicosanoid metabolism. Minor oxidative routes (COX-2, lipoxygenases, CYP) generate bioactive prostamides and hydroxy-derivatives.
FAAH is the pharmacological crux. Because a single enzyme dominates anandamide clearance, inhibiting FAAH raises AEA (and related fatty-acid amides) at the synapses already using it — a "boost the tone you already have" strategy that promised analgesia and anxiolysis without the blunt whole-brain intoxication of a direct CB1 agonist. This is why FAAH inhibitors are a genuine drug class (URB597, PF-04457845/ JNJ-42165279 in trials). It is also where the field's worst disaster happened — see Harm Reduction. FAAH genetics matter in humans: the rare FAAH-OUT loss-of-function (the "painless" Scottish patient, Habib et al., 2019) causes lifelong elevated anandamide, near-absent pain and anxiety — a natural proof-of-concept for the whole target.
Because CB1 is the most abundant GPCR in the brain and sits presynaptically on nearly every neuron class, anandamide is not a single-effect molecule but a homeostatic dimmer tuning release probability across distinct circuits — appetite, mood, pain, memory, motor control, stress recovery.
AEA tone in the mesolimbic system and prefrontal cortex modulates hedonic and motivational states; the name ānanda (bliss) reflects its role in reward-circuit fine-tuning. Endocannabinoid signaling is broadly anxiolytic and pro-hedonic when tone is adequate — and low AEA is associated with anxiety and depressive phenotypes in animal models.
Sustained aerobic exercise raises circulating anandamide, and the classic euphoria/analgesia of the "runner's high" tracks it. In mice, Fuss et al. (PNAS 2015) showed the exercise-induced anxiolysis and analgesia are blocked by CB1 antagonism but survive opioid blockade — and crucially, unlike β-endorphin, anandamide is small and lipophilic enough to cross the blood–brain barrier. The endorphin story was pharmacologically implausible; the endocannabinoid one fits.
AEA gates nociceptive input (spinal + supraspinal CB1, plus peripheral CB2/TRPV1), dampens the HPA stress axis, and is required for extinction of aversive memories — the endocannabinoid system helps the brain let go of fear. This is the therapeutic thesis behind FAAH inhibition for PTSD and anxiety: amplify the body's own recovery signal rather than flooding the receptor.
Hypothalamic and mesolimbic AEA drives feeding (the endogenous "munchies" signal); it also has potent peripheral roles — regulating embryo implantation (tightly timed low AEA is required), immune tone via CB2, and vascular/gut function. Anandamide is a whole-body lipid mediator, not just a brain molecule.
The through-line versus THC is temporal and spatial precision. Anandamide is a scalpel: released at one active synapse, gone in seconds. THC is a fog: every CB1 in the brain, for hours. That is why the endogenous molecule modulates without intoxicating, and why the smartest drugs in this space try to raise anandamide (FAAH inhibition) rather than mimic THC.
Anandamide is not a recreational drug and has no abuse or overdose profile of its own — it is a signaling lipid your body makes and destroys constantly. The real, documented danger in this space is pharmacological manipulation of the anandamide system: FAAH inhibitors and direct cannabinoids. Non-moralistic, mechanism-first.
| Target | Affinity | Rel. | Mechanism |
|---|---|---|---|
|
CB1
Cannabinoid receptor 1 (CNR1)
|
Ki ≈ 72 nM
WT range 11–300 nM
|
Partial agonist | |
|
CB2
Cannabinoid receptor 2 (CNR2)
|
Ki ≈ 180 nM
range 160–371 nM
|
Weak partial agonist | |
|
TRPV1
Vanilloid receptor 1 (capsaicin ch.)
|
EC₅₀ ≈ 1–5 µM
intracellular site
|
Agonist | |
|
FAAH
Fatty-acid amide hydrolase (substrate)
|
Km ≈ 1–10 µM
degrading enzyme
|
Substrate | |
|
GPR55 / PPARγ
Putative CB / nuclear receptor
|
µM
low potency
|
Modulator |
Anandamide binds CB1 the way THC does — a greasy, highly flexible acyl chain sliding laterally out of the membrane into a lipid-facing groove. That desolvation releases ordered water for a favorable solvent-entropy gain (positive ΔSsolv), which is how a floppy 16-rotatable-bond lipid still reaches ~72 nM affinity despite few polar contacts.
But AEA pays a steep conformational-entropy price on binding. A free arachidonoyl chain samples an enormous microstate ensemble; folding it into the U-shaped bound pose collapses that distribution — a large negative ΔSconf the FlexAID∆S tENCoM term reads as ligand-side rigidification. As a partial agonist, it narrows the receptor ensemble only part-way toward the fully active, Gi-coupled state seen in 6N4B — residual conformational entropy is retained, and the readout is submaximal efficacy.
The kinetics are an entropy story too. Anandamide's signal is fleeting not because it unbinds fast but because FAAH shreds it — the low-entropy bound complex is transient by design. Where THC's exogenous flood holds the receptor in a sustained collapsed state for hours, the endocannabinoid system spends energy to keep AEA's ordered signaling states brief and local — precision purchased by continuous synthesis and destruction.